Gilotrif

Gilotrif

None

None

None

On July 12, 2013, the FDA approved the use of Gilotrif (afatinib) for use in patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Concurrent with this action, FDA approved the therascreen EGFR RGQ PCR Kit (QIAGEN) for detection of EGFR mutations.

Jan 12, 2018 FDA granted approval to afatinib (Gilotrif) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.

This drug should be coded